Details as on January 31, 2023 |
An open ended scheme investing in Equity, Debt and Exchange Traded Commodity Derivatives and Gold ETF
Nippon India Multi Asset Fund invests in a combination of Equity, Debt, International Equity and Gold ETF/ Exchange Traded Commodity Derivatives (ETCD) and other ETCDs as permitted by SEBI from time to time. Since these asset classes are weakly/ negatively co-related and tend to perform at different periods of time, the Fund seeks to benefit from portfolio diversification. Given that asset allocation is the key to wealth creation, this fund would be an ideal offering for investors seeking a one stop solution to reap benefit of Growth of Equity, Stability of Debt & Diversification from Commodities.
August 28, 2020
Ashutosh Bhargava
Vikram Dhawan
Sushil Budhia
Tejas Sheth (Co-Fund Manager)
Kinjal Desai (Fund Manager - Overseas Investment)
Akshay Sharma (Fund Manager - Overseas Investment)
50% of S&P BSE 500 TRI, 20% of MSCI World Index TRI, 15% of Crisil Short Term Bond Fund Index & 15% of Domestic prices of Gold
Monthly Average : | ₹ 1,152.36 Cr |
Month End : | ₹ 1.152.92 Cr |
Growth Plan | ₹ 13.6568 |
IDCW Plan | ₹ 13.6568 |
Direct - Growth Plan | ₹ 14.1593 |
Direct - IDCW Plan | ₹ 14.1593 |
Entry Load: | Nil |
Exit Load: | 1% if redeemed or switched out on or before completion of 1 year
from the date of allotment of units. Nil, thereafter. |
Portfolio Turnover(Times) | 0.59 |
Average Maturity | 2.01 Years |
Modified Duration | 1.75 Years |
Annualized portfolio YTM* | 0.00% |
Macaulay Duration | 1.84 Years |
Regular/Other than Direct | 1.84 |
Direct | 0.31 |
This product is suitable for investors who are seeking*:
• Long term capital growth
• Investment in equity and equity related securities, debt & money market
instruments and Exchange Traded Commodity Derivatives and Gold ETF
Fund Riskometer
Nippon India Multi Asset Fund
Benchmark Riskometer
50% of S&P BSE 500 TRI, 20% of MSCI World Index TRI, 15% of Crisil Short Term Bond Fund Index & 15% of Domestic prices of Gold
* Investors should consult their financial advisers if in doubt about whether the product is suitable for them.